What is a stock summary page? Click here for an overview.
Business Description
Candel Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1374041093
Description
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.62 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -0.26 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -8.3 | |||||
| 3-Year EPS without NRI Growth Rate | 6 | |||||
| 3-Year FCF Growth Rate | 12.5 | |||||
| 3-Year Book Growth Rate | -14.1 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 7.59 | |||||
| 9-Day RSI | 17.58 | |||||
| 14-Day RSI | 26.24 | |||||
| 3-1 Month Momentum % | -14.53 | |||||
| 6-1 Month Momentum % | 18.5 | |||||
| 12-1 Month Momentum % | 23.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.77 | |||||
| Quick Ratio | 2.77 | |||||
| Cash Ratio | 2.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.7 | |||||
| Shareholder Yield % | -43.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -461.18 | |||||
| ROA % | -121.38 | |||||
| ROIC % | -182.64 | |||||
| 3-Year ROIIC % | -28.46 | |||||
| ROC (Joel Greenblatt) % | -1564.88 | |||||
| ROCE % | -199.92 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 32.47 | |||||
| PB Ratio | 3.39 | |||||
| Price-to-Tangible-Book | 3.39 | |||||
| EV-to-EBIT | -2.99 | |||||
| EV-to-Forward-EBIT | -4.1 | |||||
| EV-to-EBITDA | -3.05 | |||||
| EV-to-Forward-EBITDA | -2.95 | |||||
| EV-to-Forward-Revenue | 3.86 | |||||
| EV-to-FCF | -5.87 | |||||
| Price-to-GF-Value | 6.03 | |||||
| Price-to-Net-Current-Asset-Value | 3.57 | |||||
| Price-to-Net-Cash | 3.62 | |||||
| Earnings Yield (Greenblatt) % | -33.44 | |||||
| FCF Yield % | -11.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CADL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Candel Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.75 | ||
| Beta | -1.22 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 2.43 | ||
| Volatility % | 362.12 | ||
| 14-Day RSI | 26.24 | ||
| 14-Day ATR ($) | 0.699427 | ||
| 20-Day SMA ($) | 7.38625 | ||
| 12-1 Month Momentum % | 23.13 | ||
| 52-Week Range ($) | 3.785 - 14.6 | ||
| Shares Outstanding (Mil) | 47.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Candel Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Candel Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Candel Therapeutics Inc Frequently Asked Questions
What is Candel Therapeutics Inc(CADL)'s stock price today?
The current price of CADL is $4.82. The 52 week high of CADL is $14.60 and 52 week low is $3.79.
When is next earnings date of Candel Therapeutics Inc(CADL)?
The next earnings date of Candel Therapeutics Inc(CADL) is 2025-05-14 Est..
Does Candel Therapeutics Inc(CADL) pay dividends? If so, how much?
Candel Therapeutics Inc(CADL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers